Tirzepatide: A New Generation Therapeutic for Diabetes Type 2.

Endocr Metab Immune Disord Drug Targets

Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans LA 70125, United States of America.

Published: June 2023

Tirzepatide (mounjaro) is a derivative of the human glucose-dependent insulinotropic polypeptide (GIP) hormone with a position-20 being modified with 1,20- eicosanedioic acid via a chemical linker. It acts as a glucagon-like peptide-1 (GLP-1) receptor and GIP receptor agonist. It has recently been approved by FDA as an adjunct therapy to exercise and diet to improve glycemic control in patients with type II diabetes mellitus (T2DM). It represents a new transforming paradigm in the management of T2DM. This mini-review will shed light on its different pharmacokinetic and pharmacodynamic aspects.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473544PMC
http://dx.doi.org/10.2174/1871530322666221004151212DOI Listing

Publication Analysis

Top Keywords

tirzepatide generation
4
generation therapeutic
4
therapeutic diabetes
4
diabetes type
4
type tirzepatide
4
tirzepatide mounjaro
4
mounjaro derivative
4
derivative human
4
human glucose-dependent
4
glucose-dependent insulinotropic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!